RAS blocker effects on first HF hospitalization or CV death does not differ in Black and non-Black patients with HFrEF.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 39348696.
- Also identified by DOI 10.7326/ANNALS-24-02170-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Shen L, Lee MMY, Jhund PS, et al. <b>Revisiting race and the benefit of RAS blockade in heart failure: a meta-analysis of randomized clinical trials.</b> JAMA. 2024;331:2094-2104. 38809561.